Author:
Chen Yuxiao,Jian Tingfeng,Shen Yuandong
Abstract
With the fast increase in morbidity and mortality, lung cancer has become one of the greatest threats to physical health in some countries. Immune checkpoint inhibitors (ICIs) have a significant influence on the treatment landscape of lung cancer, including non-small cell lung cancer (NSCLC). This review highlights the most important ICIs used in lung cancer at present, anti-CTLA-4 and PD-1/L1. The application status, efficacy, shortcomings and prospect of each drug, including Ipilimumab (CTLA-4), Nivolumab, Pembrolizumab, and Durvalumab (PD-1/L1), are listed to show the drug indication in the current market. By comparing different drugs, the direction of ICI drug development can be more precise, which can have an important influence on choosing drugs for lung cancer treatment.
Publisher
Darcy & Roy Press Co. Ltd.
Reference37 articles.
1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018 [J]. CA: A Cancer Journal for Clinicians, 2018, 68(1): 7-30.
2. Wood D E, Kazerooni E A, Baum S L, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology [J]. Journal of the National Comprehensive Cancer Network Jnccn, 2018, 16(4):4 12-584.
3. Freddie, Bray, Jacques, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2018,68(6): 394-424.
4. Zentaro S, Kohei F, Misato O, et al. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80years or older [J]. Cancer Reports, 2021,4(6): 1405.
5. King Kong, Yao Keying, Shenxingwei, et al. Systematic evaluation and meta-analysis of PD-1/PD-L1 immunosuppressant and docetaxel in the treatment of non-small cell lung cancer [J]. Chinese Journal of Thoracic surgery, 2021, (04): 239246.